Clinical Trials Act

Section 33: Disclosure of interest

PART XI: MISCELLANEOUS PROVISIONS

Clinical Trials ActSection 33

33. Disclosure of interest (1) Where any member of the Council, Pharmacovigilance Committee or Ethics Committee, or any person related to him by blood or marriage, has a C25A – 19 [Issue 4] Clinical Trials Act financial or other material interest in relation to any matter before the Council, Pharmacovigilance Committee or Ethics Committee, as the case may be, that member— (a) shall disclose the nature of the interest at or before the meeting convened to discuss the matter; and (b) shall not take part in any deliberations of the Council, Pharmacovigilance Committee or Ethics Committee, as the case may be, relating to the matter. (2) Where any member of the Council, Pharmacovigilance Committee or Ethics Committee has or acquires any financial interest in any clinical trial in Mauritius or elsewhere, he shall inform the Council, Pharmacovigilance Committee or Ethics Committee, as the case may be, in writing, of such interest.

consolidated text (as at 2017, amended since). juris shows the text as it was consolidated; it does not confirm that this is the law in force today.

Ask juris about this section Official source